Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction

July 8, 2025 updated by: Ildar Fakhradiyev, Asfendiyarov Kazakh National Medical University

Epigenetics and Prevention of Non-communicable Diseases in Kazakhstan: a Personalized Approach and Biological Age Prediction

This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and developing health improvement recommendations.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

6720

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Kazakhstan
      • Almaty, Kazakhstan, 050000
        • Recruiting
        • Asfendiyarov Kazakh National Medical University
        • Contact:
        • Principal Investigator:
          • Ildar Fakhradiyev, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The study population consists of 6,720 adult volunteers aged 18 to 69 years, residing across 17 regions of Kazakhstan. Participants are stratified by age and gender to ensure balanced representation within the following age groups:

  • 18-29 years
  • 30-44 years
  • 45-59 years
  • 60-69 years Each age group includes an equal proportion of men and women, ensuring gender balance. The selection follows a multistage cluster sampling design, incorporating various socioeconomic backgrounds and health statuses to enhance the generalizability of findings.

Description

Inclusion Criteria:

  • Adults aged 18 to 69 years.
  • Residents of 17 regions of Kazakhstan.
  • Willingness to participate and provide informed consent.

Exclusion Criteria:

  • Age less than 18 years old or over 69 years old.
  • Failure to provide informed consent or incomplete participation in data collection procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
The study includes 1 cohort divided into 4 age subgroups.

The study follows a multistage cluster sampling design with age and gender stratification. A total of 1 cohorts have been identified, further divided into 4 age subgroups:

  1. 18-29 years
  2. 30-44 years
  3. 45-59 years
  4. 60-69 years Each age group is designed to have an equal distribution of men and women, ensuring gender balance across all subgroups.
Other: Genetic: DNA analysis
Investigation of telomere length (TL) and DNA methylation level analysis

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy of Machine Learning Model for Predicting Biological Age
Time Frame: Within 10 months from start of data collection
Evaluation of the model's performance (based on telomere length and DNA methylation) using Mean Absolute Error (MAE), Mean Squared Error (MSE), and R².
Within 10 months from start of data collection
Accuracy of Reproductive Function Prediction Model
Time Frame: Within 10 months from start of data collection
Development and validation of machine learning model to predict reproductive function using biomarkers. Model performance evaluated via MAE, MSE, and R².
Within 10 months from start of data collection

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asfendiyarov Kazakh National Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 3, 2025

Primary Completion (Estimated)

January 1, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

March 31, 2025

First Submitted That Met QC Criteria

April 23, 2025

First Posted (Actual)

May 1, 2025

Study Record Updates

Last Update Posted (Actual)

July 11, 2025

Last Update Submitted That Met QC Criteria

July 8, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BR27304987

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Kidney Diseases

Clinical Trials on Genetic: DNA analysis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe